SENP1, the major deSUMOylase, has the ability to efficiently remove SUMO-1/2/3 from their targeting substrates when overexpressed. However, Sharma et al. [3] suggested that SENP1 has a strong activity in deconjugating SUMO-1-modified substrates during mouse embryonic development. Conversely, it sustains finite efficiency in deconjugating SUMO-2/3-modified substrates. Numerous studies have confirmed that SENP1 plays an essential role in many diseases such as cardiovascular disease, diabetes and cancer via targeting GATA2, NEMO, Pin1, SMAD4, and HIF-1α for deSUMOylation ( Fig. 1) . Qiu et al. [4] indicated that graft arteriosclerosis is triggered by SENP1-mediated GATA2 deSUMOylation in endothelial cells. Notably, Shao et al. [5] revealed that SENP1 restrains type-1 diabetes progression by NEMO deSUMOylation in adipocytes. Chen et al. [6] identified a crucial role for SENP1-mediated deSUMOylation in promoting Pin1 function during breast tumorigenesis. Zhang et al. [7] demonstrated that SENP1 promotes epithelial mesenchymal transition via modulating SMAD4 deSUMOylation in prostate cancer cells. Recently, Cui et al. [8] unveiled that cancer stemness and hepatocarcinogenesis are facilitated via SENP1-mediated deSUMOylation for HIF-1α.
Hypoxia-inducible factors (HIFs) function as heterodimeric complexes that consist of the oxygen-sensitive subunit HIF-1/2α and oxygen-insensitive HIF-1β subunit [9] . Under the conditions of hypoxia, HIFα subunits dimerize with HIF-1β to escape from proteolysis. The HIF dimer translocates to the nucleus to facilitate the expressions of hundreds of target genes closely related to cell survival, invasiveness, angiogenesis, proliferation, and metabolic adaptation. HIF targets, in turn, will trigger tumor resistance to chemotherapeutic drugs and metastasis, as well as enhancing the stabilization/amplification of liver CSCs [10] , although the formation mechanism of liver CSCs is still largely unknown. Nowadays, Cui et al. [8] shed a further light on the relationship between HCC progression and HIF-1α. In their study, they identified that hypoxia, through the involvement of HIF-1α and HIF-2α, can efficiently increase the stemness in HCC cells. They also found that SENP1 is the firsthand target of HIF-1α and HIF-2α. Of note, these authors provided the first evidence that there is a positive feedback loop especially between HIF-1α subunit and SENP1. So, it is meaningful to explore what signaling pathways may affect the feedback loop in order to effectively cure the HCC.
How about the role of SENP1 in modulating the effect of HIF-1α on cancer stemness? Cheng et al. [11] reported that SENP1 deSUMOylates and stabilizes HIF-α in hypoxia. They confirmed that hypoxia triggers HIF-1α SUMOylation, which enhances HIF-1α degradation via a von Hippel-Lindau (VHL) protein and proteasomedependent mechanism. Cui et al. [8] focused their study on hypoxiainduced CSC subpopulation, involvement in SENP1-knockdown and overexpression both in vivo and in vitro. They also confirmed that the accumulation of SUMO-1-conjugated or SUMO-2/3-conjugated HIF-1α is significantly increased in SENP1-knockdown HCC cells. Furthermore, they found that SENP1 can inhibit the SUMOylation of HIF-1α at K391 and K477 sites by means of its SUMO protease catalytic activity, and then upregulate the expressions of HIF target genes, including stemness-related genes (Nanog, Oct4, and CD24) and SENP1. These interesting results showed that SENP1 is involved in liver CSC features and hepatocarcinogenesis by regulating of HIF-1α deSUMOylation in hypoxia. However, the authors fail to find significant conjugation between SUMO and HIF-2α in HCC cells. Interestingly, the important role of SENP1 in liver CSC properties makes itself a novel promising therapy target. Inhibitors of SENP1, like the small molecule inhibitors (JCP-666, VEA-260, VEA-499, and GN6958) and the natural products (triptolide and Momordin), are also important for the treatment of HCC [12] . Among the small molecule inhibitors, JCP-666 and VEA-260 are small molecule inhibitors of plasmodium falciparum SENP1 (PfSENP1). VEA-499 is the most effective inhibitor for SENP1 and SENP2 in human. Notably, GN6958 is not only the most effective compound which selectively suppresses SENP1, but also inhibits HIF-1α without influencing tubulin expression in HeLa cells. In view of the double inhibition effects of GN6958, it may become the most potential targeted drug for HCC. The triptolide and the Momordin are also targets of SENP1. Several inhibitors of SENP isoforms, such as 1,2,5-oxadiazoles, 2-(4-chlorophenyl)-2-oxoethyl 4-benzamidobenzoate analogs and SI2, have also been found.
In summary, deSUMOylation plays crucial roles in regulating specific substrates that are involved in cellular DNA repair, proliferation, apoptosis, growth, and survival. SENP1, by its SUMO protease catalytic activity, not only is involved in liver CSC properties and hepatocarcinogenesis, but also plays a vital role in other diseases like breast cancer, diabetes and cardiovascular diseases. Therefore, drugs targeting for SENP1 may open a new avenue of therapeutic intervention to hold back HCC growth, extrahepatic metastasis, and intrahepatic recurrence, as well as other diseases.
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